Matthew Parris
Chief Tech/Sci/R&D Officer bei TRAWS PHARMA, INC.
Profil
Matthew Parris is currently working as the Vice President-Clinical Operations at Traws Pharma, Inc. He previously worked as the Director-Clinical Operations at Aegerion Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. He also held the position of Vice President-Clinical Development at Eleison Pharmaceuticals, Inc. Mr. Parris completed his undergraduate degree at Imperial College London.
Aktive Positionen von Matthew Parris
Unternehmen | Position | Beginn |
---|---|---|
TRAWS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01.08.2018 |
Ehemalige bekannte Positionen von Matthew Parris
Unternehmen | Position | Ende |
---|---|---|
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | - |
AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Matthew Parris
Imperial College London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
TRAWS PHARMA, INC. | Health Technology |
INOVIO PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |